Long Term Treatment With L-DOPS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00889135
Recruitment Status : Approved for marketing
First Posted : April 28, 2009
Last Update Posted : October 18, 2016
Information provided by (Responsible Party):
David Robertson, Vanderbilt University

Brief Summary:
This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.

Condition or disease Intervention/treatment
Dopamine Beta Hydroxylase (DBH) Deficiency Drug: droxidopa

Study Type : Expanded Access
Official Title: Long Term Treatment With L-DOPS
Study Start Date : September 2004
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Droxidopa
U.S. FDA Resources

Intervention Details:
    Drug: droxidopa
    Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
    Other Names:
    • L-DOPS
    • DOPS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years old or older with orthostatic hypotension
  • established diagnosis of DBH deficiency and fractionated plasma catecholamine levels that show high dopamine levels and very low norepinephrine and epinephrine levels. Blood pressure increase in response to oral treatment with L-DOPS during previous studies.

Exclusion Criteria:

  • subjects with orthostatic hypotension that do not have a genetic form of the disorder and catecholamine pattern is not consistent with that above.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00889135

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: David Robertson, M.D. Vanderbilt University Medical Center

Responsible Party: David Robertson, Professor of Medicine and Pharmacology, Vanderbilt University Identifier: NCT00889135     History of Changes
Other Study ID Numbers: 041037
First Posted: April 28, 2009    Key Record Dates
Last Update Posted: October 18, 2016
Last Verified: October 2016

Additional relevant MeSH terms:
Antiparkinson Agents
Anti-Dyskinesia Agents